Validation of recombinant Sendai virus in a non-natural host model

@article{Griesenbach2011ValidationOR,
  title={Validation of recombinant Sendai virus in a non-natural host model},
  author={Uta Griesenbach and Gerry Mclachlan and Toshiyuki Owaki and Lucinda Somerton and Ting Shu and Alison Baker and Peter A. Tennant and Catherine Gordon and Christina Vrettou and Emma Baker and David D S Collie and Mamoru Hasegawa and Eric W F W Alton},
  journal={Gene Therapy},
  year={2011},
  volume={18},
  pages={182-188}
}
We have previously shown that recombinant Sendai virus (SeV) vector, derived from murine parainfluenza virus, is one of the most efficient vectors for airway gene transfer. We have also shown that SeV-mediated transfection on second administration, although reduced by 60% when compared with levels achieved after a single dose, is still high because of the efficient transfection achieved by SeV vector in murine airways. Here, we show that these levels further decrease on subsequent doses. In… 
Sendai Virus, a Strong Inducer of Anti-Lentiviral State in Ovine Cells
TLDR
Observations may boost new approximations in ameliorating the SRLV burden by stimulation of the innate immune response using SeV-based vaccine vectors.
Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis
TLDR
The data support the progression of the F/HN-pseudotyped lentiviral vector into a first-in-man CF trial in 2017 and the impact of pre-existing and acquired immunity against the vector and vector stability in several clinically relevant delivery devices was assessed.
Integrating Viral and Nonviral Vectors for Cystic Fibrosis Gene Therapy in the Airways
TLDR
The importance of correcting the appropriate cell types, options for integrating vectors, animal models for CF gene therapy, and clinically relevant endpoint measurements are discussed, which improve the ability to deliver transposons to the airways in vivo.
Concept and Technology Underlying Sendai Virus (SeV) Vector Development
TLDR
The conceptual novelty of the SeV vector and the technology used to accommodate a foreign gene of interest into the full-length SeV genome are described and the generation of non-transmissible safer vector versions are described.
Efficient Gene Delivery to Pig Airway Epithelia and Submucosal Glands Using Helper-Dependent Adenoviral Vectors
TLDR
Helper-dependent vectors carrying human CFTR or reporter gene LacZ were aerosolized intratracheally into pigs under bronchoscopic guidance and it was found that the LacZ reporter and hCFTR transgene products were efficiently expressed in lung airway epithelial cells.
Viral vectors for cystic fibrosis gene therapy: What does the future hold?
TLDR
Preclinical and clinical research related to viral CF gene therapy is reviewed and appropriately pseudotyped LV vectors are promising candidates forCF gene therapy.
Current Status and Future Directions of Gene and Cell Therapy for Cystic Fibrosis
Although the development of gene therapy for cystic fibrosis (CF) was high priority for many groups in academia and industry in the first 10–15 years after cloning the cystic fibrosis transmembrane
Intratracheal aerosolization of viral vectors to newborn pig airways
TLDR
A technique for aerosolization of viral vectors to the airways of newborn pigs and a fine mist is sprayed into the distal trachea for widespread and uniform distribution of transgene expression is described.
Towards gene therapy for primary ciliary dyskinesia
TLDR
Functional DNAH5 cDNA was cloned from healthy airway cells and the cDNA validated by sequencing and expression studies, and a non-viral vector was optimised, characterised and used to deliver DNAH 5 coding minicircle DNA to PCD models but poor transfection efficiency of DNAH4 prevented functional correction.
Expert opinion in biological therapy: update on developments in lung gene transfer
TLDR
One of the most significant developments in recent years is the generation of lentiviral vectors which efficiently transduce lung tissue and focused and coordinated efforts assessing lentivirus safety and scaling up lentiv virus production will be required to move this vector into clinical lung gene therapy studies.
...
1
2
3
...

References

SHOWING 1-10 OF 27 REFERENCES
A defective nontransmissible recombinant Sendai virus mediates efficient gene transfer to airway epithelium in vivo
TLDR
The development of an F-defective nontransmissible SeV, which can still efficiently mediate gene transfer to the airway epithelium, represents the first important step towards the use of a cytoplasmic RNA viral vector in clinical trials of gene therapy.
Repeat Transduction in the Mouse Lung by Using Adeno-Associated Virus Vectors with Different Serotypes
TLDR
AAV6 vectors pseudotyped with capsid proteins from AAV serotypes 2, 3, and 6 for readministration in the mouse lung found that an AAV6 vector transduced airway epithelial and alveolar cells in the lung at rates that were at least as high as those of AAV2 pseudotype vectors, while transduction rates mediated by AAV3 were much lower.
Lack of Repeat Transduction by Recombinant Adeno-Associated Virus Type 5/5 Vectors in the Mouse Airway
TLDR
The results suggest that without the development of an effective and clinically acceptable immunosuppression strategy, treatments for chronic diseases that require repeated administration of rAAV5/5 vectors will be unsuccessful.
Efficient gene transfer to airway epithelium using recombinant Sendai virus
TLDR
It is shown that recombinant Sendai virus (SeV) produces efficient transfection throughout the respiratory tract of both mice and ferrets in vivo, as well as in freshly obtained human nasal epithelial cells in vitro.
Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered
TLDR
It is shown that AAV2/9 can be readministered in the presence of high levels of serum-circulating neutralizing antibodies as early as 1 month after initial exposure, with minimal effect on overall reporter gene expression, rendering it a promising gene transfer vector candidate for use in humans.
Successful transgene expression with serial doses of aerosolized rAAV2 vectors in rhesus macaques.
  • A. Fischer, S. Beck, +6 authors W. Guggino
  • Biology, Medicine
    Molecular therapy : the journal of the American Society of Gene Therapy
  • 2003
TLDR
This study is the first to demonstrate successful gene transfer subsequent to repeated aerosolized doses of rAAV2 in immunocompetent nonhuman primates without associated inflammatory responses prohibitive to transgene expression.
Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes.
TLDR
The data suggest that this lentiviral vector may provide a step change in airway transduction efficiency relevant to a clinical programme of gene therapy for CF.
Effect of tolerance induction to immunodominant T-cell epitopes of Sendai virus on gene expression following repeat administration to lung
TLDR
Findings indicate that impeding the adaptive T-cell response to the immunodominant viral epitope is not sufficient to prevent the process to eradicate viruses from the lung, and these findings indicate that T- cell tolerance was, paradoxically, associated with a more profound extinction of viral expression.
Pseudotyped Lentivirus Vectors Derived from Simian Immunodeficiency Virus SIVagm with Envelope Glycoproteins from Paramyxovirus
TLDR
The mutant SeV F- and HN-pseudotyped SIVagm vector was able to transduce various types of animal and human cell lines and have considerable potential for effective use in gene therapy for various therapies, including respiratory diseases.
Sendai virus-mediated CFTR gene transfer to the airway epithelium
TLDR
This work has identified a novel method to allow the cystic fibrosis transmembrane conductance regulator (CFTR) cDNA sequence to be inserted within SeV (SeV-CFTR).
...
1
2
3
...